Atrial fibrillation

21 trials 8 recruiting MedDRA PT
21 Registered trials
8 Recruiting
16 Unique sponsors
22 Unique IMPs
9 Commercial trials
Drug classes (ATC)
— ATC code not specified 10
N Neurology/Psychiatry (ATC N) 2
B Haematology (ATC B) 8
V Various (ATC V) 1
C Cardiology (ATC C) 2
M Musculoskeletal (ATC M) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 14 substances
Factor Xa inhibitor (DOAC) 3 substances
Monoclonal antibody 1 substance
Heparin / LMWH 1 substance
Antiplatelet / NSAID 1 substance
Direct thrombin inhibitor (DOAC) 1 substance
GLP-1 receptor agonist 1 substance
Phase III: 7 Phase II/III: 1 Phase II: 2 Phase III/IV: 2 Phase IV: 8 Phase I: 1 Phase I (Other): 1

Filter these 21 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 21 trials

Phase III

7 trials
  • Anthos Therapeutics Inc. Commercial
    ABELACIMAB
    2023-503224-66-00 15 countries 2023 n=1,729
    Recruiting
  • Bayer AG Commercial
    APIXABAN; ASUNDEXIAN
    2023-503794-38-00 22 countries 2022 n=9,578
    Ended
  • Janssen - Cilag International Commercial
    ANDEXANET ALFA; APIXABAN; MILVEXIAN
    2022-501419-15-00 19 countries 2023 n=6,819
    Ended
  • Hamilton Health Sciences Corporation Academic
    IMP not specified
    2023-504504-28-00 1 country 2024 n=1,000
    Recruiting
  • Insel Gruppe AG Academic
    IMP not specified
    2023-509717-36-00 7 countries 2024 n=1,700
    Recruiting
  • Uniwersytet Medyczny Im. Karola Marcinkowskiego W Poznaniu Academic
    ALLOPURINOL
    2024-517610-15-00 1 country 2024 n=1,116
    Recruiting
  • Hamilton Health Sciences Corporation Academic
    IMP not specified
    2023-504504-28-00 1 country 2024 n=1,000
    Recruiting

Phase II/III

1 trial

Phase II

2 trials
  • Acesion Pharma ApS Commercial
    AP31969 SULFATE
    2025-521377-14-00 7 countries 2025 n=180
    Recruiting
  • Anthos Therapeutics Inc. Commercial
    ABELACIMAB; RIVAROXABAN
    2023-509066-38-00 3 countries 2021 n=896
    Ended

Phase III/IV

2 trials
  • Assistance Publique Hopitaux De Paris Academic
    IMP not specified
    2024-516374-29-00 1 country 2023 n=550
    Ended
  • Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy Academic
    HEPARIN SODIUM
    2024-516376-15-00 1 country n=410
    Pending

Phase IV

8 trials
  • Olpha AS Commercial
    ETHACIZINE
    2025-521267-13-01 1 country n=30
    Pending
  • Centre hospitalier universitaire de Liege Academic
    ACETYLSALICYLIC ACID; APIXABAN; CLOPIDOGREL; DABIGATRAN ETEXILATE; EDOXABAN; RIVAROXABAN
    2025-520954-12-00 1 country n=250
    Pending
  • Hamilton Health Sciences Corporation Academic
    EDOXABAN
    2024-518508-31-00 10 countries n=380
    Pending
  • Icahn School Of Medicine At Mount Sinai Academic
    ACETYLSALICYLIC ACID; APIXABAN; CLOPIDOGREL; CLOPIDOGREL HYDROGEN SULFATE; DABIGATRAN ETEXILATE; EDOXABAN; PHENPROCOUMON; RIVAROXABAN; TICAGRELOR
    2024-515924-35-00 1 country 2023 n=750
    Recruiting
  • Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy Academic
    IMP not specified
    2024-516384-93-00 1 country n=80
    Pending
  • Rijnstate Ziekenhuis Stichting Academic
    SEMAGLUTIDE
    2022-501392-81-00 1 country 2024 n=280
    Ended
  • University Of Ottawa Heart Institute Academic
    ACETYLSALICYLIC ACID; RIVAROXABAN
    2024-518736-37-00 2 countries 2018 n=282
    Ended
  • UZ Leuven Academic
    AMIODARONE HYDROCHLORIDE; FLECAINIDE ACETATE; SOTALOL
    2025-525121-13-00 1 country n=988
    Pending

Phase I

1 trial
  • Acesion Pharma ApS Commercial
    IMP not specified
    2023-505424-57-00 1 country 2023 n=142
    Ended

Phase I (Other)

1 trial
  • Bayer AG Commercial
    IMP not specified
    2025-524043-12-00 1 country 2026 n=72
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Hamilton Health Sciences Corporation Academic 3 Phase III, Phase IV 2
Acesion Pharma ApS Commercial 2 Phase I, Phase II 1
Bayer AG Commercial 2 Phase I (Other), Phase III 1
Anthos Therapeutics Inc. Commercial 2 Phase II, Phase III 1
Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy Academic 2 Phase III/IV, Phase IV 0
Xyra LLC Commercial 1 Phase II/III 0
Janssen - Cilag International Commercial 1 Phase III 0
Olpha AS Commercial 1 Phase IV 0
Assistance Publique Hopitaux De Paris Academic 1 Phase III/IV 0
Insel Gruppe AG Academic 1 Phase III 1
Uniwersytet Medyczny Im. Karola Marcinkowskiego W Poznaniu Academic 1 Phase III 1
Centre hospitalier universitaire de Liege Academic 1 Phase IV 0
Icahn School Of Medicine At Mount Sinai Academic 1 Phase IV 1
Rijnstate Ziekenhuis Stichting Academic 1 Phase IV 0
University Of Ottawa Heart Institute Academic 1 Phase IV 0
UZ Leuven Academic 1 Phase IV 0
New trials by year
2021
1
2022
1
2023
5
2024
5
2025
1
2026
1
← All indication landscapes